Generic Reform Hearings Set In Senate, But McCain/Schumer Lacks Vehicle
This article was originally published in The Tan Sheet
Executive Summary
Sen. Edward Kennedy (D-Mass.) has committed to generic drug reform hearings in the Health Committee this spring, Capitol Hill staffer Missy Rohrbach told the Generic Pharmaceutical Association annual meeting in Coral Gables, Fla. April 9
You may also be interested in...
Generic Drug Competition Hearing Planned For Senate Commerce Cmte.
The Senate Commerce Committee is tentatively planning to hold a hearing on anticompetitive practices affecting generic drug marketing in April or May
Generics study
Office of Management & Budget clears FTC request to conduct study on Hatch/Waxman's effects on competition between branded and generic drug manufacturers; OMB approval was not deemed clear-cut, since former Eli Lilly exec Mitch Daniels heads the office. FTC will issue special orders to 30 innovator companies and 70 generics firms questioning impact of Hatch/Waxman's 180-day marketing exclusivity and 30-month stay provisions on innovation; firms must reply within 60 days. Study was first proposed last fall (1"The Tan Sheet" Oct. 16, 2000, p. 13)
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC